The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.
With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback